Polymyositis as a manifestation of chronic graft‐versus‐host disease after allo‐<scp>HSCT</scp>

Meng, Lijuan; Ji, Suqiong; Wang, Qiong; Bu, Bitao

doi:10.1002/ccr3.1709

Cited by 12 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Their results showed rituximab to be highly effective in the treatment of PM. The mechanisms underlying the treatment effects could be associated with the immunosuppression mediated by the blockage of autoantibody of B lymphocytes [26] . For our patients, rituximab was used for the second round of treatment and it showed good effects.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Polymyositis in a child with thalassemia after hematopoietic stem cell transplantation

et al. 2021

View full text Add to dashboard Cite

Rationale:Polymyositis (PM) is a rare neuromuscular phenotype of chronic graft-versus-host disease (cGVHD). Although glucocorticoids have been shown to be effective in the treatment of PM, most people experience poor treatment response and poor prognosis.Patient concerns:A six-year-old boy with thalassemia received allogeneic hematopoietic stem cell transplantation (HSCT) and consequently developed sudden myasthenia of limbs 17 months after the transplant.Diagnoses:Medical history, current symptoms, laboratory examinations, and imaging findings of the patient indicated cGVHD complicated with PM.Interventions:He was then given high-dose corticosteroid therapy, including tacrolimus, ruxolitinib, and rituximab.Outcomes:Twenty-three months after transplantation, creatine kinase levels returned to normal range, and the MRI showed that the original muscle edema signal was significantly improved. The patient's muscle weakness continued to improve, and his overall condition was good.Lessons:This report suggests that glucocorticoids combined with immunosuppressants may be effective against polymyositis. Rituximab and ruxolitinib may be a good choice in treating polymyositis.

show abstract

Section: Discussionmentioning

confidence: 98%

“…The mechanisms underlying the treatment effects could be associated with the immunosuppression mediated by the blockage of autoantibody of B lymphocytes. [ 26 ] For our patients, rituximab was used for the second round of treatment and it showed good effects. However, treatment was often discontinued due to financial issues.…”

Section: Discussionmentioning

confidence: 99%

Polymyositis in a child with thalassemia after hematopoietic stem cell transplantation

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Currently, two principle categories of IMNM, anti-signal recognition particle (SRP) autoantibodies-IMNM (SRP-IMNM) and anti-3-hydroxy-3-methylglutaryl-coa reductase (HMGCR) autoantibodies-IMNM (HMGCR-IMNM) (5,6), account for the largest proportion of IMNM and are relatively the most described. Other subtypes, including seronegative IMNM, connective tissue disease-related IMNM, statin-related IMNM, cancer-related IMNM, and immune checkpoint inhibitorsinduced IMNM are also reported (7)(8)(9)(10)(11)(12). The detection of serum anti-SRP autoantibodies in IIM is much earlier than that of anti-HMGCR autoantibodies.…”

Section: Introductionmentioning

confidence: 99%

Anti-SRP immune-mediated necrotizing myopathy: A critical review of current concepts

2022

Front. Immunol.

View full text Add to dashboard Cite

Purpose of reviewThis review aims to describe clinical and histological features, treatment, and prognosis in patients with anti-signal recognition particle (SRP) autoantibodies positive immune-mediated necrotizing myopathy (SRP-IMNM) based on previous findings.Previous findingsAnti-SRP autoantibodies are specific in IMNM. Humoral autoimmune and inflammatory responses are the main autoimmune characteristics of SRP-IMNM. SRP-IMNM is clinically characterized by acute or subacute, moderately severe, symmetrical proximal weakness. Younger patients with SRP-IMNM tend to have more severe clinical symptoms. Patients with SRP-IMNM may be vulnerable to cardiac involvement, which ought to be regularly monitored and cardiac magnetic resonance imaging is the recommended detection method. The pathological features of SRP-IMNM are patchy or diffuse myonecrosis and myoregeneration accompanied by a paucity of inflammatory infiltrates. Endoplasmic reticulum stress-induced autophagy pathway and necroptosis are activated in skeletal muscle of SRP-IMNM. Treatment of refractory SRP-IMNM encounters resistance and warrants further investigation.SummaryAnti-SRP autoantibodies define a unique population of IMNM patients. The immune and non-immune pathophysiological mechanisms are involved in SRP-IMNM.

show abstract

Current Concepts and Future Prospects in Immune-Mediated Myopathies

Gaspar¹

2023

Immune-Mediated Myopathies and Neuropathies

View full text Add to dashboard Cite

Polymyositis as a manifestation of chronic graft‐versus‐host disease after allo‐HSCT

Cited by 12 publications

References 11 publications

Polymyositis in a child with thalassemia after hematopoietic stem cell transplantation

Polymyositis in a child with thalassemia after hematopoietic stem cell transplantation

Anti-SRP immune-mediated necrotizing myopathy: A critical review of current concepts

Current Concepts and Future Prospects in Immune-Mediated Myopathies

Contact Info

Product

Resources

About